A Single Center, Prospective, Double-blind, Balanced, Randomized, Two-treatment, Single-period, Single Ascending Dose (SAD) and Multiple-dose, Parallel, Phase I, Study to Compare the Safety, Tolerability and Pharmacokinetics of Test Formulation VRP-034 (Novel Formulation of Polymyxin B 500,000 IU) of Venus Remedies Limited vs Commercially Available Polymyxin B for Injection USP (Poly-MxB) 500,000 IU in Normal Healthy Adult Male Human Subjects
Latest Information Update: 07 Apr 2026
At a glance
- Drugs Polymixin B (Primary)
- Indications Gram-negative infections
- Focus Pharmacodynamics
- Sponsors Venus Remedies
Most Recent Events
- 07 Apr 2026 New trial record